Teva Pharma (TEVA) / Mylan (MYL) Combo Unlikely, Says Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Goldman Sachs Comments on Mylan (MYL) Following Yesterday's Rumors (TEVA) (ABT)
October 3, 2014 8:04 AM EDTGoldman Sachs maintained Buy rating on Mylan (NASDAQ: MYL) with a price target of $60. Comments follow yesterday's M&A chatter. Analyst Jami Rubin noted that Mylan is at a competitive disadvantage given lower tax rates at peers Actavis plc (NYSE: ACT),Perrigo (NYSE:... More
Standpoint Research Downgrades Teva Pharma (TEVA) to Hold
October 2, 2014 11:15 AM EDTStandpoint Research downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $52.99 yesterday.
... More